SCHEMBL2885192

SCHEMBL2885192

Cc1cccc([N+](=O)[O-])c1-c1ccccc1C(=O)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MYC P01106 1/20 0.69
▸ TSHR P16473 3/20 0.60
▸ TDP1 Q9NUW8 2/20 0.56
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ HSD17B10 Q99714 2/20 0.50
▸ LMNA P02545 1/20 0.49
▸ KCNMA1 Q12791 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ FABP4 P15090 1/20 0.47
▸ ALDH1A1 P00352 4/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ S100A4 P26447 2/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ PTPRC P08575 1/20 0.46
▸ CTSD P07339 1/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ GAA P10253 1/20 0.45
▸ CRHBP P24387 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19608973 0.82 HSD17B10 (0.62) TSHRTDP1L3MBTL1HSD17B10LMNA
SCHEMBL9512847 0.82 MYC (1.00) MYCTSHRTDP1L3MBTL1HSD17B10
Toluic Acid SCHEMBL27625583 0.81 TSHR (0.67) MYCTSHRTDP1L3MBTL1HSD17B10
SCHEMBL4439669 0.79 TSHR (0.59) TSHRTDP1LMNASMN1; SMN2ALDH1A1
SCHEMBL13133450 0.79 TSHR (0.56) TSHRTDP1L3MBTL1LMNASMN1; SMN2
SCHEMBL29471725 0.79 TSHR (0.68) TSHRTDP1L3MBTL1ALDH1A1MEN1
SCHEMBL8610738 0.79 TSHR (0.68) TSHRTDP1L3MBTL1ALDH1A1MEN1
Toluic Acid SCHEMBL6271080 0.79 TSHR (0.64) MYCTSHRTDP1L3MBTL1HSD17B10
Toluic Acid SCHEMBL6271086 0.79 TSHR (0.64) MYCTSHRTDP1L3MBTL1HSD17B10
SCHEMBL2885196 0.79 TSHR (0.73) MYCTSHRTDP1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283373-B2 Inhibitors of cytosolic phospholipase A2 PFIZER INC. (US) 2012-10-09 — — US disclosed
EP-1891006-B1 INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 WYETH LLC (US) 2010-11-24 — — EP disclosed
EP-2248801-A1 Inhibitors of cytosolic phospholipase a2 Wyeth LLC (US) 2010-11-10 — — EP disclosed
US-20100029645-A1 Inhibitors of Cytosolic Phospholipase A2 WYETH LLC 2010-02-04 — — US disclosed
US-20100022536-A1 Inhibitors of Cytosolic Phospholipase A2 NOVARTIS AG (CH) 2010-01-28 — — US disclosed
US-7557135-B2 Inhibitors of cytosolic phospholipase A2 WYETH (US) 2009-07-07 — — US disclosed
EP-1891006-A2 INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 Wyeth a Corporation of the State of Delaware (US) 2008-02-27 — — EP disclosed
US-20070004719-A1 Inhibitors of cytosolic phospholipase A2 WYETH (US) 2007-01-04 — — US disclosed
WO-2006128142-A2 INHIBITORS OF CYTOSOLIC PHOSPHOLIPASE A2 WYETH (US) 2006-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022536-A1 Inhibitors of Cytosolic Phospholipase A2 PLA2G4B, PLA2G4A, PLA2G12A MYC 4743/4885TSHR 4125/4885TDP1 1941/4885
US-20100029645-A1 Inhibitors of Cytosolic Phospholipase A2 PLA2G4B, PLA2G4A, PLA2G12A MYC 4743/4885TSHR 4125/4885TDP1 1941/4885
US-20070004719-A1 Inhibitors of cytosolic phospholipase A2 PLA2G4B, PLA2G4A, PLA2G12A MYC 4743/4885TSHR 4125/4885TDP1 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback